Analysts expect surge in profit for Aventis; gain of about 40% seen for first nine months

Article Abstract:

Aventis is in talks to sell its non-core businesses and might also be entertaining pharmaceutical acquisitions. These plans plus strong drug sales collectively put its net profits and forecasts in a good position going forward. Its best-selling drugs are Lovenox, Taxotere and Allegra.

Acquisitions and mergers, Statistics

---

Sanofi outlines plan to revamp Aventis: suitor would overhaul research and development to boost lab productivity

Article Abstract:

Sanofi S.A. officials have targeted Aventis S.A.'s research and development unit as a candidate for reorganization provided Sanofi is able to acquire the company. The production of vaccines and oncology drugs would be emphasized.

Acquisitions & mergers, Mergers, acquisitions and divestments, Company acquisition/merger, Sanofi S.A., Company business planning

---

Bayer is changing its prescription for a turnaround

Article Abstract:

Bayer may enter a life sciences contract with a partner to instigate a turnaround for the company. The partner has not been identified.

Germany, Bayer AG, Company Profile, BAYZY

Similar abstracts:

• Abstracts: Unilever profit soars 26%, aided by sale of unit. Fiat changes board, sees more troubles. Car division of Fiat swings to operating profit
• Abstracts: Food for thought. Developing a taste for acquisitions
• Abstracts: ABB's 10% rise in net profit disappoints. ABB tops forecasts, lifts net 17%, boosting shares. Influential chairman quits engineering giant ABB
• Abstracts: ING plans to cut about 1,600 jobs at its U.S. business. Bipop cuts profit on provisions for bad loans. Fortis cuts forecast for full-year earnings
• Abstracts: Skandia gives opposing view room in plan. Aegon may seek acquisition in U.S. Skandia of Sweden creates three units, shuffles executives

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.